Gradual dosing of Lilly drug for Alzheimer’s disease reduces risk of brain swelling
Starting a more gradual dosing schedule for Eli Lilly’s Alzheimer’s disease drug Kisunla reduces the percentage of patients suffering from potentially serious brain swelling, according to interim results from a late-stage study presented at a medical meeting Tuesday.
POPULAR POSTS
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVE STREAM